Indeed, if the clinical trial demonstrates that 16p11.2 BP2–3 deletion carriers lose a significant amount of weight, this will provide orthogonal evidence of the contribution of SH2B1 to the obesity of deletion carriers, as people with common obesity are unlikely to respond to MC4R agonism. Here, SH2B1 is linked to obesity disorder.